胰腺癌死亡率占恶性肿瘤第4位，在分子水平进行早期诊疗是改善预后的关键。GPC1在胰腺癌中高表达，在正常胰腺组织及良性病变中低表达或不表达。冬凌草甲素（ORI）能抑制肿瘤细胞的增殖、诱导凋亡。选择以GPC1为胰腺癌特异性靶点，以金纳米笼为载体，构建载ORI，以PH/酶敏感的透明质酸控制给药闸门的荧光、CT和MR靶向探针，利用投射电镜、动态光散射等对其性能进行检测；对探针与胰腺癌细胞和胰腺导管上皮细胞等进行系列体外毒性和药代动力学实验，采用MTT、Transwell等技术检测。将探针注入胰腺癌小鼠模型，进行活体荧光、CT、MR成像，取肿瘤和瘤周组织进行分子病理学检测；并和载吉西他滨探针组、未载药探针组、单纯吉西他滨组对照；最后，将影像和病理结果进行对比分析。本研究通过载ORI靶向多模态探针的体内外实验，在靶向分子成像的同时，进行靶向药物递送、定点释放、靶向治疗，希望实现胰腺癌早期诊疗一体化。

The mortality of pancreatic cancer accounts for the fourth in malignant tumors，early diagnosis at molecular level is the key to improving prognosis. GPC1 is highly expressed in pancreatic cancer, and low expression or no expression in normal pancreatic tissues and benign lesions. Oridonin can inhibit the proliferation of tumor cells, leading to the apoptosis of tumor cells. Choosing GPC1 as a specific target of pancreatic cancer, and the gold cage used as the carrier, to establish the targeted probe loading Oridonin with fluorescence, CT, MRI imaging, controlled by the PH/ enzyme sensitive hyaluronic acid. The qualities and functions of the probe were tested by using transmission electron microscopy, dynamic light scattering and so on. Pancreatic cancer cells and pancreatic ductal epithelial cells with probes were taking series experiments of in vitro toxicity and pharmacokinetic, taking technical tests，such as MTT, transwell, flow cytometry and so on. The probes were injected into the mouse model of pancreatic cancer, subjected to fluorescence, CT and MRI imaging in vivo, and then the tumor tissues and the surrounding tissues were tested by molecular pathology. Setting up the loaded gemcitabine targeted probe group, unloaded drug targeted probe group and gemcitabine group as control groups. Finally, the imaging and pathological results were compared. The in vitro and in vivo study of ORI loading multiprobes with targeted molecular imaging is to realize site-specific delivery and therapy, which is expecting to diagnose and treat pancreatic cancer at early stage.